Table 2.
Baseline characteristics of ESRD patients undergoing transplantation.
| Variables | Transplanted ESRD patients n = 95 |
| Donor age, yr | 40.6 ± 10.9 |
| Donor sex male, n (%) | 45 (47.4) |
| Donor vital status, n (%) | |
| Living | 88 (92.6) |
| Deceased | 7 (7.4) |
| Recipient age, years | 31.0 ± 8.6 |
| Recipient sex male, n (%) | 67 (70.5) |
| Combination of donor/recipient sex, n (%) | |
| Male/Male | 30 (31.6) |
| Male/Female | 15 (15.8) |
| Female/Male | 36 (37.9) |
| Female/Female | 13 (13.7) |
| Unknown/Male | 1 (1.0) |
| Induction therapy, n (%) | |
| BSX | 42 (44.2) |
| THY | 38 (40.0) |
| THY, IVIG | 11 (11.6) |
| THY, IVIG, RIX, PPH | 1 (1.1) |
| THY, IVIG, BSX, PPH | 1 (1.1) |
| THY, IVIG, PPH | 2 (2.0) |
| Maintenance immunosuppression, n (%) | |
| TAC, MMF, PDN | 84 (88.4) |
| CYA, MMF, PDN | 11 (11.6) |
| Follow-up after transplantation, months | 4.0 ± 1.6 |
| eGFR at follow-up, mL/min/1.73 m2 | 77.5 ± 25.0 |
| H3cit at follow-up, ng/mL | 31.5 ± 29.3 |
| PAD4 at follow-up, ng/mL | 7.0 ± 11.4 |
Data are expressed as mean ± standard error of the mean. BSX = basiliximab, CYA = cyclosporine A, eGFR = estimated glomerular filtration rate, H3cit = citrullinated histone H3, IVIG = intravenous immunoglobulin, MMF = mycophenolate mofetil, PAD4 = Peptidyl arginine deiminase 4, PDN = prednisone, PPH = plasmapheresis, RIX = rituximab, TAC = tacrolimus, THY = thymoglobulin.